Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease
Identifieur interne : 002411 ( Main/Exploration ); précédent : 002410; suivant : 002412Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease
Auteurs : Yaroslau Compta [Espagne] ; María J. Martí [Espagne] ; Naroa Ibarretxe-Bilbao [Espagne] ; Carme Junqué [Espagne] ; Francesc Valldeoriola [Espagne] ; Esteban Mu Oz [Espagne] ; Mario Ezquerra [Espagne] ; Jose Ríos [Espagne] ; Eduardo Tolosa [Espagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-11-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Amyloid, Amyloid beta-Peptides (cerebrospinal fluid), Case-Control Studies, Cerebrospinal fluid, Dementia, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Mental Processes (physiology), Mental Status Schedule, Middle Aged, Multivariate Analysis, Nervous system diseases, Neuropsychological Tests, Parkinson Disease (cerebrospinal fluid), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Phosphorylation (physiology), Retrospective Studies, Statistics as Topic, beta‐amyloid, cerebrospinal fluid, dementia, neuropsychological function, tau, tau Proteins (cerebrospinal fluid).
- MESH :
- chemical , cerebrospinal fluid : Amyloid beta-Peptides, tau Proteins.
- cerebrospinal fluid : Parkinson Disease.
- physiology : Mental Processes, Phosphorylation.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- Aged, Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Mental Status Schedule, Middle Aged, Multivariate Analysis, Neuropsychological Tests, Retrospective Studies, Statistics as Topic.
Abstract
Alzheimer's disease (AD)‐pathology may play a role in Parkinson's disease (PD)‐related dementia (PDD). The aim of this study was to assess cerebrospinal fluid (CSF) levels of tau, phospho‐tau, and beta‐amyloid, proposed AD biomarkers, and their relationship with cognitive function in PD. Forty PD patients [20 nondemented (PDND); 20 PDD] and 30 controls underwent CSF tau, phospho‐tau, and beta‐amyloid analysis using specific ELISA techniques. All PD patients and 15 controls underwent neuropsychological testing of fronto‐subcortical (attention, fluency) and neocortical (memory, naming, visuoperceptive) functions. CSF markers levels were compared between groups, and compared and correlated with neuropsychological measures in PDND and PDD separately and as a continuum (PD). CSF tau and phospho‐tau were higher in PDD than in PDND and controls (P < 0.05). CSF beta‐amyloid ranged from high (controls) to intermediate (PDND) and low (PDD) levels (P < 0.001). In all PD and PDD patients, high CSF tau and phospho‐tau were associated with impaired memory and naming. In PDND, CSF beta‐amyloid was related with phonetic fluency. These findings suggest underlying AD‐pathology in PDD in association with cortical cognitive dysfunction, and that low CSF beta‐amyloid in PDND patients with impaired phonetic fluency can constitute an early marker of cognitive dysfunction. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22594
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B68
- to stream Istex, to step Curation: 000B68
- to stream Istex, to step Checkpoint: 001013
- to stream PubMed, to step Corpus: 001B41
- to stream PubMed, to step Curation: 001B41
- to stream PubMed, to step Checkpoint: 001F14
- to stream Ncbi, to step Merge: 002839
- to stream Ncbi, to step Curation: 002839
- to stream Ncbi, to step Checkpoint: 002839
- to stream Main, to step Merge: 002C72
- to stream PascalFrancis, to step Corpus: 000D18
- to stream PascalFrancis, to step Curation: 002001
- to stream PascalFrancis, to step Checkpoint: 000F55
- to stream Main, to step Merge: 003052
- to stream Main, to step Curation: 002411
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease</title><author><name sortKey="Compta, Yaroslau" sort="Compta, Yaroslau" uniqKey="Compta Y" first="Yaroslau" last="Compta">Yaroslau Compta</name></author><author><name sortKey="Marti, Maria J" sort="Marti, Maria J" uniqKey="Marti M" first="María J." last="Martí">María J. Martí</name></author><author><name sortKey="Ibarretxe Ilbao, Naroa" sort="Ibarretxe Ilbao, Naroa" uniqKey="Ibarretxe Ilbao N" first="Naroa" last="Ibarretxe-Bilbao">Naroa Ibarretxe-Bilbao</name></author><author><name sortKey="Junque, Carme" sort="Junque, Carme" uniqKey="Junque C" first="Carme" last="Junqué">Carme Junqué</name></author><author><name sortKey="Valldeoriola, Francesc" sort="Valldeoriola, Francesc" uniqKey="Valldeoriola F" first="Francesc" last="Valldeoriola">Francesc Valldeoriola</name></author><author><name sortKey="Mu Oz, Esteban" sort="Mu Oz, Esteban" uniqKey="Mu Oz E" first="Esteban" last="Mu Oz">Esteban Mu Oz</name></author><author><name sortKey="Ezquerra, Mario" sort="Ezquerra, Mario" uniqKey="Ezquerra M" first="Mario" last="Ezquerra">Mario Ezquerra</name></author><author><name sortKey="Rios, Jose" sort="Rios, Jose" uniqKey="Rios J" first="Jose" last="Ríos">Jose Ríos</name></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D3532C6682933CC0328E0C7334A7EA83065A6165</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22594</idno><idno type="url">https://api.istex.fr/document/D3532C6682933CC0328E0C7334A7EA83065A6165/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B68</idno><idno type="wicri:Area/Istex/Curation">000B68</idno><idno type="wicri:Area/Istex/Checkpoint">001013</idno><idno type="wicri:doubleKey">0885-3185:2009:Compta Y:cerebrospinal:tau:phospho</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19795497</idno><idno type="wicri:Area/PubMed/Corpus">001B41</idno><idno type="wicri:Area/PubMed/Curation">001B41</idno><idno type="wicri:Area/PubMed/Checkpoint">001F14</idno><idno type="wicri:Area/Ncbi/Merge">002839</idno><idno type="wicri:Area/Ncbi/Curation">002839</idno><idno type="wicri:Area/Ncbi/Checkpoint">002839</idno><idno type="wicri:Area/Main/Merge">002C72</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:10-0036259</idno><idno type="wicri:Area/PascalFrancis/Corpus">000D18</idno><idno type="wicri:Area/PascalFrancis/Curation">002001</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000F55</idno><idno type="wicri:doubleKey">0885-3185:2009:Compta Y:cerebrospinal:tau:phospho</idno><idno type="wicri:Area/Main/Merge">003052</idno><idno type="wicri:Area/Main/Curation">002411</idno><idno type="wicri:Area/Main/Exploration">002411</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease</title><author><name sortKey="Compta, Yaroslau" sort="Compta, Yaroslau" uniqKey="Compta Y" first="Yaroslau" last="Compta">Yaroslau Compta</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències (ICN), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Marti, Maria J" sort="Marti, Maria J" uniqKey="Marti M" first="María J." last="Martí">María J. Martí</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències (ICN), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Ibarretxe Ilbao, Naroa" sort="Ibarretxe Ilbao, Naroa" uniqKey="Ibarretxe Ilbao N" first="Naroa" last="Ibarretxe-Bilbao">Naroa Ibarretxe-Bilbao</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Psychiatry and Clinical Psychobiology IDIBAPS, CIBERNED, Faculty of Medicine, University of Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Junque, Carme" sort="Junque, Carme" uniqKey="Junque C" first="Carme" last="Junqué">Carme Junqué</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Psychiatry and Clinical Psychobiology IDIBAPS, CIBERNED, Faculty of Medicine, University of Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Valldeoriola, Francesc" sort="Valldeoriola, Francesc" uniqKey="Valldeoriola F" first="Francesc" last="Valldeoriola">Francesc Valldeoriola</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències (ICN), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Mu Oz, Esteban" sort="Mu Oz, Esteban" uniqKey="Mu Oz E" first="Esteban" last="Mu Oz">Esteban Mu Oz</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències (ICN), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Ezquerra, Mario" sort="Ezquerra, Mario" uniqKey="Ezquerra M" first="Mario" last="Ezquerra">Mario Ezquerra</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències (ICN), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Rios, Jose" sort="Rios, Jose" uniqKey="Rios J" first="Jose" last="Ríos">Jose Ríos</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Statistics and Methodologic Support Unit, Unitat d'Avaluació, Suport i Prevenció (UASP), Hospital Clínic, IDIBAPS, Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències (ICN), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-11-15">2009-11-15</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="2203">2203</biblScope><biblScope unit="page" to="2210">2210</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D3532C6682933CC0328E0C7334A7EA83065A6165</idno><idno type="DOI">10.1002/mds.22594</idno><idno type="ArticleID">MDS22594</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Amyloid</term><term>Amyloid beta-Peptides (cerebrospinal fluid)</term><term>Case-Control Studies</term><term>Cerebrospinal fluid</term><term>Dementia</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Humans</term><term>Male</term><term>Mental Processes (physiology)</term><term>Mental Status Schedule</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Nervous system diseases</term><term>Neuropsychological Tests</term><term>Parkinson Disease (cerebrospinal fluid)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (psychology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Phosphorylation (physiology)</term><term>Retrospective Studies</term><term>Statistics as Topic</term><term>beta‐amyloid</term><term>cerebrospinal fluid</term><term>dementia</term><term>neuropsychological function</term><term>tau</term><term>tau Proteins (cerebrospinal fluid)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Amyloid beta-Peptides</term><term>tau Proteins</term></keywords><keywords scheme="MESH" qualifier="cerebrospinal fluid" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Mental Processes</term><term>Phosphorylation</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Case-Control Studies</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Humans</term><term>Male</term><term>Mental Status Schedule</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Neuropsychological Tests</term><term>Retrospective Studies</term><term>Statistics as Topic</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Amyloïde</term><term>Démence</term><term>Liquide céphalorachidien</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Alzheimer's disease (AD)‐pathology may play a role in Parkinson's disease (PD)‐related dementia (PDD). The aim of this study was to assess cerebrospinal fluid (CSF) levels of tau, phospho‐tau, and beta‐amyloid, proposed AD biomarkers, and their relationship with cognitive function in PD. Forty PD patients [20 nondemented (PDND); 20 PDD] and 30 controls underwent CSF tau, phospho‐tau, and beta‐amyloid analysis using specific ELISA techniques. All PD patients and 15 controls underwent neuropsychological testing of fronto‐subcortical (attention, fluency) and neocortical (memory, naming, visuoperceptive) functions. CSF markers levels were compared between groups, and compared and correlated with neuropsychological measures in PDND and PDD separately and as a continuum (PD). CSF tau and phospho‐tau were higher in PDD than in PDND and controls (P < 0.05). CSF beta‐amyloid ranged from high (controls) to intermediate (PDND) and low (PDD) levels (P < 0.001). In all PD and PDD patients, high CSF tau and phospho‐tau were associated with impaired memory and naming. In PDND, CSF beta‐amyloid was related with phonetic fluency. These findings suggest underlying AD‐pathology in PDD in association with cortical cognitive dysfunction, and that low CSF beta‐amyloid in PDND patients with impaired phonetic fluency can constitute an early marker of cognitive dysfunction. © 2009 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Espagne</li></country></list><tree><country name="Espagne"><noRegion><name sortKey="Compta, Yaroslau" sort="Compta, Yaroslau" uniqKey="Compta Y" first="Yaroslau" last="Compta">Yaroslau Compta</name></noRegion><name sortKey="Ezquerra, Mario" sort="Ezquerra, Mario" uniqKey="Ezquerra M" first="Mario" last="Ezquerra">Mario Ezquerra</name><name sortKey="Ibarretxe Ilbao, Naroa" sort="Ibarretxe Ilbao, Naroa" uniqKey="Ibarretxe Ilbao N" first="Naroa" last="Ibarretxe-Bilbao">Naroa Ibarretxe-Bilbao</name><name sortKey="Junque, Carme" sort="Junque, Carme" uniqKey="Junque C" first="Carme" last="Junqué">Carme Junqué</name><name sortKey="Marti, Maria J" sort="Marti, Maria J" uniqKey="Marti M" first="María J." last="Martí">María J. Martí</name><name sortKey="Mu Oz, Esteban" sort="Mu Oz, Esteban" uniqKey="Mu Oz E" first="Esteban" last="Mu Oz">Esteban Mu Oz</name><name sortKey="Rios, Jose" sort="Rios, Jose" uniqKey="Rios J" first="Jose" last="Ríos">Jose Ríos</name><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><name sortKey="Valldeoriola, Francesc" sort="Valldeoriola, Francesc" uniqKey="Valldeoriola F" first="Francesc" last="Valldeoriola">Francesc Valldeoriola</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002411 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002411 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D3532C6682933CC0328E0C7334A7EA83065A6165
|texte= Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |